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Abstract
Background: Statin treatment is common among 80+ people, but little is known about statin effects on health-related quality of life (HRQoL) 
in this oldest age group.
Methods: In the Helsinki Businessmen Study (HBS), men born from 1919 to 1934 (original n = 3,490), have been followed-up since the 
1960s. In 2015, a questionnaire about lifestyle, diseases, and medications, and including RAND-36/SF-36 HRQoL instrument was mailed to 
survivors. About 612 men (72.6%) responded, 530 of them reporting their medications (98% community-living). Propensity score analysis 
was used to compare statin users and nonusers for HRQoL.
Results: We compared 229 current statin users (median age 85 years, interquartile range 84–88 years) with 301 nonusers (86; 84–89 years). 
Current statin users had had significantly higher serum cholesterol level in midlife (p < .001), but current lifestyle-related characteristics were 
similar in users and nonusers. Statin users reported more hypertension (61.1%, p < .001), diabetes (23.6%, p <.001), and atherosclerotic 
cardiovascular disease (ASCVD, 33.6%, p <.001), than nonusers. Statin users reported higher mean scores than nonusers in all eight RAND-36 
subscales, but after adjustments for multiplicity and a propensity score we found no significant differences between statin users and nonusers. 
Stratification for primary (no ASCVD) and secondary (with CVD) prevention supported the main results.
Conclusions: Our study suggests that statin treatment has no significant effect on health-related quality of life among octogenarian, community-
dwelling men. The results contradict concerns about statin treatment in the oldest-old, and may caution against deprescribing of statins due 
to old age alone.
Keywords: Quality of life; Statin treatment; SF-36; Multimorbidities; Drug-related; Frailty.
Octogenarians form an increasing age group in societies, and also 
use of statin medication is very frequent among them. Although 
there are no randomized trials on statin treatment performed specifi-
cally in 80+ individuals (1,2), observational studies have suggested 
that statins would have various benefits irrespective of age, frailty, 
or nutritional status (1,3–11). There are also contradictory results 
about statin treatment in older individuals (1,12,13), especially in 
the 80+ group (14). Consequently, the safety of statins and effects 
on health related quality of life (HRQoL) among older patients and 
in primary prevention may be of concern (2,15), for example due 
to well known statin effects on muscle symptoms or risk of diabe-
tes (16). Although these concerns are accentuated in patients with 
terminal disease (17,18), adverse effects may also impair function 
and QoL among older people in general. Therefore, statin treatment 
may be a target for discontinuation and “deprescribing” (17–19) in 
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on QoL and statin use in older people living in the community, we 
investigated this among men with median age of 86 years, 61% of 




These are secondary analyses of the Helsinki Businessmen Study 
(HBS), a cohort of men born 1919–1934 (original n = 3,490), who 
have been followed-up since the 1960s (20,21). Their cardiovascu-
lar disease risk factor history (including serum cholesterol values) is 
known since midlife (mean age 40 years), and their statin use was 
previously known up to 2010/2011. In 2015, current addresses were 
retrieved from the Population Information System of Finland for 
843 surviving HBS participants, and a questionnaire survey about 
lifestyle, medications, prevalent physician-diagnosed diseases, and 
health-related QoL (HRQoL, RAND-36/SF-36 instrument, https://
www.rand.org/health/surveys_tools/mos/36-item-short-form.html, 
22) was sent to them.
The questionnaire was returned by 612 men (72.6%), with 
530 of them presenting a detailed medication list. Of the respond-
ers, 520 (98%) were community-living with an age ranging from 
80 to 95  years. Primary and secondary prevention of atheroscler-
otic cardiovascular disease (ASCVD) were defined as the absence 
or presence of any of the following reported conditions: coronary 
artery disease, cerebrovascular disorder (stroke), or peripheral artery 
disease. Subjective happiness was assessed using a 100-mm scale 
(0 = most unhappy, 100 = most happy), where the participant was 
asked to draw X on the point to reflect his feeling of happiness. The 
men were also asked of their latest cholesterol level, and 292 men 
reported this.
RAND-36/SF-36 HRQoL instrument includes eight subscales: 
Role limitations caused by physical health problems (Role physical, 
RP), Role limitations caused by emotional problems (Role emo-
tional, RE), Vitality (VT), Mental health (MH), Social functioning 
(SF), Bodily pain (BP), and General health (GH). Scores in subscales 
range from 0 to 100, with 100 representing the best level of function-
ing or wellbeing. A difference of 3–5 points in the RAND-36 sub-
scales is considered to be clinically important (22). Use of RAND-36 
has been validated in the Finnish population (23).
The prevalence of phenotypic prefrailty and frailty could be 
assessed in 487 men using the simplified Women’s Health Initiative 
(sWHI) frailty score which has been shown to correlate well with 
the standard Cardiovascular Health Study (CHS) frailty phenotype 
(24). Accordingly, we used two items from the RAND-36 Physical 
function (the capacity to walk one block and scored as severe [two-
points]), moderate [1-point], or no limitation [0]), and Vitality sub-
scales (feeling tired most or all of the time [1-point] vs less often [0]), 
one item for physical activity, and one item for weight loss. A total 
score of 3 or more defined frailty, a score of 1 or 2 defined pre-frailty, 
and 0 indicated nonfrailty.
The follow-up has been approved by the ethical committee of the 
Department of Medicine, Helsinki University Central Hospital. The 
study is registered as ClinicalTrials.gov identifier: NCT02526082.
Statistical Analysis
Descriptive statistics, Armitage test for trend in proportions, and 
analysis of covariance (ANCOVA) were used to compare statin users 
with nonusers. The ANCOVA analyses were adjusted for age, but 
because statin users had more comorbidity possibly affecting QoL—
and may differ also in other respects from nonusers—the presence 
of health conditions and lifestyle factors were adjusted using a pro-
pensity score. The propensity score, defined as the conditional prob-
ability of using statins given the individuals covariates (25), was built 
using the logistic regression model with age, economic situation, liv-
ing with a spouse, feeling of happiness, alcohol use, BMI, frailty, 
prevalent diseases (hypertension, diabetes, chronic arrhythmia, 
pulmonary disease, heart failure, atherosclerotic vascular disease 
[ASCVD], musculoskeletal disease) as predictors. The propensity 
score was further divided into quintiles and used as a categorical pre-
dictor in the regression models. The 95% confidence intervals were 
adjusted for multiplicity using Bonferroni’s correction procedure. 
Statistical analyses were performed using NCSS statistical software 
(Kaysville, UT, www.ncss.com, version 8).
Results
We compared the 229 men currently on statin treatment (median 
age 85, interquartile range 84–88  years) with the 301 men not 
using statins (median age 86; interquartile range 84–89 years); their 
characteristics are presented in Table 1. Among statin nonusers in 
2015 we identified 71 men who had discontinued statin for undeter-
mined reasons after 2010/2011, and their characteristics are shown 
for comparison. Among the men, 299 (61.4%), 165 (33.9%), and 
23 (4.7%) men were nonfrail, prefrail, and frail, respectively. There 
was no significant difference in frailty status between statin users 
and nonusers (p = .14). Compared to nonusers, current statin users 
had had significantly higher serum cholesterol level in midlife (mean 
6.72 mmol/L, SD 1.1 vs 6.12 mmol/L, SD 1.1; p < .001), but lower 
reported cholesterol level in 2015 (p < .001). Statin users reported 
more hypertension (p < .001), diabetes (p < .001), CAD (p < .001), 
and cerebrovascular disorders (p =  .04) than nonusers; of the sta-
tin users and nonusers 52.4% and 28.6% had ASCVD, respectively 
(p < .001). There was no statistically significant difference in the 
prevalence of cancer, heart failure, chronic arrhythmia, pulmonary 
disease, or musculoskeletal disease.
Scores of the eight RAND-36 subscales are shown in Table 2. 
Although the means of all subscales were found to be higher among 
statin users than all nonusers, we observed no significant differences 
between the two groups in age-adjusted nor in propensity score-
adjusted analyses, also corrected for multiplicity. The scores in scales 
were generally lower among those who had discontinued statins 
after 2010/2011 (Table 2).
Finally, we compared RAND-36 subscales between statin users 
and nonusers separately in primary (no ASCVD) and secondary 
(history of ASCVD) prevention (Table 3). Men without ASCVD had 
generally higher mean values of all RAND-36 subscales than men 
with ASCVD, but otherwise the stratified, adjusted analyses sup-
ported the results of the main analysis presented in Table 2.
Discussion
Although octogenarian, community-living statin users had more 
comorbidity than nonusers of statins, we found no significant dif-
ferences in HRQoL (RAND-36 subscales) between the two groups. 
Our results contradict frequent concerns about statin treatment in 
the oldest-old, one fear being worsened QoL due to adverse effects, 
for example muscle pain.
In a randomized, unblinded trial of terminal patients expected 
to live less than 1  year, discontinuation of statin treatment was 
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associated with better QoL (17). However, the interpretation of the 
results is not unequivocal (26), and in an unblinded trial a reversal 
of nocebo effect (27) cannot be excluded. In our cohort, statin users 
reported their HRQoL without knowing the purpose of the present 
study on statins.
Among the 71 men, who had discontinued statin treatment, 
HRQoL was generally lower than that of current statin users, 
but differences were not statistically significant. Reasons of dis-
continuation were undetermined, and men with worsened QoL 
due to statin treatment could have been overrepresented among 
nonusers. Nonadherence has been reported to be especially high 
among patients older than 75 years (28), but reasons are usually 
related to lifestyle, not necessarily adverse effects (29). In accord-
ance, discontinuation of statins due to adverse effects has been 
relatively rare in blinded studies (16), which can adjust for the 
nocebo effect inflating adverse effects (27) and leading to discon-
tinuation in real life. Despite the possibility for muscle adverse 
effects, statin treatment did not seem to disturb exercise in the 
LIFE study (30).
As expected, statin users had more cardiovascular morbidity, but 
they also tended to have differences in living conditions and lifestyle 
which could affect QoL. On the other hand, statin treatment has 
beneficial effects on vascular function (31), anti-inflammatory effects 
(32), and generally low frequency of real adverse effects (16), all of 
which would be mechanisms to affect HRQoL, too. Therefore, the 
analyses were adjusted for using a propensity score analysis in order 
to tease out potential statin-specific effects on HRQoL. We also per-
formed stratified analyses in primary (without prevalent ASCVD) 
Table 1. Characteristics of Statin Users and Nonusers
Variable







Current Statin  
User in 2015, n = 229
p Between Statin  
Users and All Nonusers*
Age, y, (interquartile range) 86 (84–89) 86 (84–89) 87 (84–90) 85 (84–88) .014
Cholesterol in midlife, 
mmol/L
6.12 (0.06) 5.97 (0.08) 6.54 (0.1) 6.72 (0.07) <.001
Reported cholesterol in 2015, 
mmol/L, available from 292 
men
4.6 (0.1) 4.7 (0.1) 4.3 (0.2) 3.7 (0.1) <.001
BMI, kg/m2 24.7 (0.2) 24.7 (0.2) 24.8 (0.4) 25.0 (0.2) .24
Nonsmokers, n (%) 298 (99.0) 233 (96.9) 70 (98.6) 226 (98.7) .37
Alcohol, g/week 60.8 (4.8) 59.9 (6.0) 77.0 (9.9) 58.0 (5.5) .81
Living with a spouse, n (%) 204 (67.8) 156 (67.7) 46 (65.2) 172 (75.1) .037
Economic status, n (%) .23
 Good 212 (70.4) 168 (73.0) 44 (62.3) 168 (73.3)
 Satisfactory 86 (28.6) 60 (26.1) 26 (36.2) 59 (25.8)
 Bad 3 (1.0) 2 (0.9) 1 (1.4) 2 (0.9)
Regular physical activity, %) 219 (72.8) 166 (72.2) 53 (74.6) 169 (73.8) .39
 Hours/week (among those 
with regular activity)
5.0 (0.3) 5.0 (0.4) 5.1 (0.6) 5.0 (0.3) .99
Regular medication, n (%) 251 (83.4) 182 (79.1) 69 (97.2) 229 (100) <.001
Happiness, mm† 73.1 (0.9) 73.3 (1.0) 72.7 (1.7) 74.2 (1.0) .39
Stable weight during past 
3 months, n (%)
234 (77.7) 183 (79.6) 51 (71.8) 179 (78.2) .40
Phenotypic frailty assessed in 
487 men, n (%)
.14
 Nonfrail 162 (59.3) 145 (63.2) 38 (54.0) 137 (64.0)
 Prefrail 97 (35.5) 71 (30.8) 30 (42.9) 68 (31.8)
 Frail 14 (5.1) 14 (6.0) 2 (3.2) 9 (4.2)
Reported diseases, n (%)
 Diabetes 34 (11.3) 21 (9.1) 13 (18.3) 54 (23.6) <.001
 Hypertension 139 (46.2) 103 (44.8) 36 (50.7) 140 (61.1) <.001
 CAD 46 (15.3) 19 (8.3) 27 (38.0) 77 (33.6) <.001
 Cerebrovascular disorder 31 (10.3 19 (10.1) 12 (16.9) 35 (15.3) .043
 PAD 39 (13.0) 23 (10.0) 16 (22.5) 40 (17.5) .075
 Heart failure 49 (16.3) 31 (13.5) 18 (24.9) 40 (17.5) .36
 Chronic arrhythmia 86 (28.6) 59 (25.7) 27 (38.0) 71 (31.0) .27
 ASCVD‡ 87 (28.9) 50 (21.7) 37 (52.1) 121 (52.8) <.001
 Chronic lung disease 33 (11.0) 23 (10.0) 10 (14.1) 23 (10.0) .37
 Cancer 65 (21.6) 50 (21.7) 15 (21.1) 47 (20.5) .38
 Musculoskeletal disease 105 (34.9) 76 (33.0) 29 (40.8) 76 (33.2) .34
Notes: Continuous variables are mean (SE). ASCVD = atherosclerotic cardiovascular disease; CAD = coronary artery disease; PAD = Peripheral artery disease; 
BMI = body mass index.
*Adjusted for age; analysis of covariance (ANCOVA) for continuous variables, Armitage test for trend in proportions. †100 mm line, 0 = most unhappy, 
100 = most happy. ‡CAD, cerebrovascular disorder, or PAD.
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and secondary (with ASCVD) prevention which support results in 
the whole cohort; HRQoL was not significantly different between 
users and nonusers of statins.
Main limitation of our study is that the cohort of male survivors 
in a long-term observational study is obviously selected, and over 
60% were assessed to be nonfrail. The results nevertheless give infor-
mation about the associations between statins and HRQoL among 
community-dwelling octogenarians in real life, and robust or near-
robust individuals nevertheless form a substantial proportion of the 
older population in primary care. A further strength of this homogen-
ous population from the highest social strata is that socioeconomic 
factors have not been likely to affect the use of statins (which at 
the time of study were generic in Finland). Healthy user bias—those 
adhering to statin treatment have also better QoL in the first place—
is possible in a cross-sectional study. However, greater comorbid-
ity, especially that of cardiovascular diseases, and similar or higher 
long-term burden of risk factors in statin users of our cohort (33) 
do not support it. Moreover, there were no significant differences 
between users and nonusers in several lifestyle-related factors (BMI, 
alcohol consumption, smoking, physical activity, economic status), 
which were nevertheless taken into account in the propensity score 
analysis. Still, residual confounding is always possible in an obser-
vational study, and lack of significant difference does not prove that 
HRQoL of statin users and nonusers would be equivalent. Although 
means of several HRQoL subscales were higher among statin users, 
clinically meaningful difference in RAND-36 subscales is considered 
to be 3–5 points (22), and lower limits of all confidence intervals 
were clearly below these. Finally, use of statin was self-reported, but 
higher cholesterol level in midlife and lower reported cholesterol 
level in statin users in 2015 suggest that self-report in this cohort 
is reliable.
In conclusion, our observational study among octogenarian, 
community-dwelling men showed no significant difference in the 
health-related quality of life between statin users and nonusers. This 
neutral finding adds to the cardiovascular benefits of statins and may 
caution against deprescribing of statins due to old age alone.
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